We use cookies to create the most secure and effective website possible for our customers.





Splittera allows to site-specifically modify antibodies with toxins (Antibody drug conjugates, ADCs), fluorescent probes, DNA, peptides and proteins, rendering homogeneous products in a very efficient and cost-effective process.

Splittera for site-specific antibody modification:

- covalently incorporates payloads to the C-terminus of the heavy and light chains of an antibody, yielding DAR 2 or DAR 4 (DAR, drug to antibody ratio)

- the affinity of the antibody for the antigen is not affected

- allows to modify the antibody with two different molecules by using two orthogonal ZIP's inteins, achieving DAR 2+2 in a single reaction

-it can be applied to any antibody format, including bispecific antibodies, Fabs, svFc and others


Learn more in our Site-specific antibody conjugation flyer